Lexeo Acquires Mantle for $8.3 Million to Expand Friedreich Ataxia Pipeline
Deal adds oral and brain-targeted FA treatments to Lexeo’s pipeline. LX2006 gene therapy stays top priority, with pivotal data due in late 2027.
/ 5 items
#LXEO↓
Eye Doctor and Fox News Regular Eyed as New Head of FDA Vaccine Division
FDA may pick Dr. Hemmati to lead CBER, which could speed up vaccine and biotech drug approvals, but decision is not final.
Biotech Analyst Picks Signal Major Upside Into 2026
Analysts highlight Alumis, Foghorn, and Lexeo as biotech stocks with strong clinical catalysts and significant upside potential into 2026.
Cantor Fitzgerald Starts Coverage on Lexeo Therapeutics with Strong Outlook
Cantor Fitzgerald initiates coverage of Lexeo Therapeutics with an Overweight rating, praising its cardiac gene therapy programs and transparent updates.
Lexeo's Friedreich Ataxia Treatment Accelerates FDA Review
Lexeo Therapeutics' gene therapy, LX2006, is moving faster toward FDA approval for Friedreich's ataxia cardiomyopathy.